Home | Coverage | Agents | Pulse | LogIn |
| Darwin Score | +42 |
| Ticker | NEU |
| Latest Price | 14.28 AUD as of close on 04-Jul-2025 |
| 3 Month price range | 8.72 to 14.28 AUD |
| Market Capitalisation | 1.81Bn AUD |
| Country | Australia |
| Region | Asia |
| Economic Sector | Health Care |
| Business Sector | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Sub-Industry | Pharmaceuticals |
| Description | Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia. See More ... |
| Company URL | https://www.neurenpharma.com |
| See Darwins Full Analysis for Neuren Pharmaceuticals Ltd |
Tell Me About (TMA) is Darwins structured scoring system for assets. Here are the scores from the key TMA sections for Neuren Pharmaceuticals Ltd. Further information and full detail is available when you login.
| TMA Part | Focus of Analysis | TMA Score |
|---|---|---|
| Price | Analysis of performance, trend, RSI, OBV and moving averages | +20 |
| Sentiment | News and Candle Patterns. | -1 |
| Fundamentals | Analyst Ratings, Valuation and Dividend analysis. | +7 |
| Flow | Institutional, Fund and Insider buying and selling. | 0 |
| Models | Forecast models. | +16 |
There are 2 live alerts for Neuren Pharmaceuticals Ltd. All the alerts are negative.
There are 6 peers of Neuren Pharmaceuticals Ltd.
| Asset Name | Industry Group | Perf(20d)% | Asset Score |
|---|---|---|---|
| Cann Group Ltd (CAN) | Pharmaceuticals | +30.8 | 0 |
| Ecofibre Ltd (EOF) | Pharmaceuticals | 0 | -8 |
| Firebrick Pharma Ltd (FRE) | Pharmaceuticals | -6.0 | -12 |
| Mayne Pharma Group Ltd (MYX) | Pharmaceuticals | +3.5 | -15 |
| Medical Developments International Ltd (MVP) | Pharmaceuticals | -2.0 | +9 |
| Starpharma Holdings Ltd (SPL) | Pharmaceuticals | -3.2 | -15 |
To see complete information on Neuren Pharmaceuticals Ltd or any other assets please login.
If you do not already have an account you can register for a free trial of our service. This will let you explore all the analytical information we have on price, fundamantals, flow, sentiments & models for all the stocks under coverage. You will then be able to compare asset scores and perform a wide range of multi asset analysis such as Market Cycles and Relative Scores.
Follow Us | |
©2025 Darwin Knows - All Rights Reserved | |